Background: Cancer is considered as the main public health problem and the second leading
cause of morbidity and mortality worldwide. Numerous environmental-lifestyle related risk factors
account for around one-third of cancer deaths. Recently, the key role of lncRNAs has been widely investigated
in a variety of disorders, including cancer. The lncRNA GHET1 has been considered as an
essential oncogenic lncRNA in many types of human cancers. Clinical investigations indicated that expression
of lncRNA GHET1 is correlated with clinicopathological characteristics in cancer. This metaanalysis
investigated the correlation between the lncRNA GHET1 expression and clinicopathological
features in different types of cancers.
Materials and Methods: Comprehensive literature searches in PubMed, Scopus, and Web of
Knowledge were conducted up to April 11, 2019. Sixteen studies were included in this meta-analysis.
All statistical analyses were conducted using Stata software, version 12.0.
Results: The pooled OR and 95%CIs of the sixteen relevant studies showed that over expression of
lncRNA GHET1 was associated with tumor-size ≥5 cm (OR= 2.51, 95% CI: 1.89-3.33, p=0.00,
I2=38.30%), positive lymph node metastasis (OR= 2.83, 95% CI: 1.78-4.52, p=0.00, I2=45.60%), advanced
tumor stage (OR= 3.92, 95% CI: 2.97-5.19, p=0.00, I2=0.00%), positive distant metastasis
(OR= 5.74, 95% CI: 2.58-12.77, p=0.00, I2=0.00%), advanced tumor status (OR= 2.97, 95% CI: 1.40-
6.29, p=0.01, I2=34.70%), and positive vascular invasion (OR= 2.69, 95% CI: 1.61-4.50, p=0.00,
Conclusion: Taken together, the current study demonstrated that overexpression of lncRNA GHET1 is
significantly associated with clinicopathological features in human cancers. Our results suggested that
lncRNA GHET1 can be utilized as a prognostic biomarker in human cancer.